Data Driven Utilization Management, Purpose Built for Oncology
Oncology Analytics® provides health plans, providers, and patients with a data-driven, utilization management solution that delivers real-world, evidence-based analytics focused exclusively for oncology
Oncology Analytics Raises $21 Million Series B Financing Led by Oak HC/FT
Prominent healthcare investor Oak HC/FT joined by McKesson Ventures, Blue Cross Blue Shield Venture Partners and Sandbox Advantage Fund to Accelerate Patient-First Oncology Benefits Management
Today’s cancer treatments are varied, complicated and costly. Oncology treatment costs are soaring and forecast to hit $105 billion in the US by 2023, driven primarily by availability and favorable reimbursement of new medicines.
Oncology Analytics provides the critical missing link for health plans by helping to manage the total cost of cancer care. By providing access to current, evidence-based, disease-specific analytics on all cancer types and treatment options, backed by board-certified oncology physicians and pharmacists, health plans are able to provide their members with the ability to achieve the best possible outcomes.
Improved outcomes are possible when treatment options are tailored to the unique needs of the patient. Ensuring that patients receive the optimal treatment that balances efficacy, toxicity and affordability lie at the heart of Oncology Analytics’ mission.
Utilization Management, Purpose Built for Oncology
The Oncology Analytics e-Prior Authorization platform is purpose-built for oncology to efficiently evaluate and approve high-quality and high-value treatments for cancer care.
Serial Healthcare Tech Entrepreneur to Lead Company’s Technical Innovation and Expansionread more
Next-generation analytics software solution equips health plans with superior cancer treatment decision-making capabilities through improved access to clinical oncology dataread more
Serial entrepreneur brings 30 years of healthcare leadershipread more
Articles & Press
Cancer drug spending by health plans and employers has nearly doubled in the past five years and is expected to double again by 2022. In 2018 alone, 15 new cancer drugs and 55 new indications for existing cancer drugs were approved by the FDA, compared to just seven...read more
The RELAY Trial: A “Race” Between Erlotinib Plus Ramucirumab vs. Erlotinib Plus Placebo in EGFR (+) Metastatic Non-Small Cell Lung Cancer (mNSCLC)
The following article, written by Marjorie Velasquez, a Clinical Oncology Pharmacist at Oncology Analytics, is the fourth and final article of a four-part series on key trends and findings from the American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago May 31-June 4, 2019.read more